NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

Ying Mu, PhD, DABT

Practice Area Focus

  • Biologics
  • Cell Therapy
  • Combination Products
  • Devices
  • Drugs
  • Monoclonal Antibodies
  • Toxicology
  • Clinical Pharmacology
  • PKPD
  • Gene Therapy
  • Development Strategy
  • Drug Safety
  • Health Technology Assessment
  • Immunology
  • Orthopedics


Ying Mu, PhD, DABT joined NDA Partners as an Expert Consultant in 2017. He is a board-certified toxicologist with nine years of experience at FDA in the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER).

Dr. Mu was formerly Toxicologist and Principal Investigator in the Division of Biology, Chemistry, and Materials Science, Office of Science and Engineering Laboratories (CDRH), and Pharmacology and Toxicology Reviewer in the Division of Special Pathogen and Transplant Products, Office of New Drugs (CDER). Prior to his FDA career, he was a Research Assistant Professor in the School of Pharmacy at the University of Pittsburgh.

Dr. Mu is a highly-respected toxicologist with more than 25 years of life sciences research experience and a broad array of knowledge, including biomarker, toxicology, pharmacology, immunology, cell therapy, stem cell, tissue engineering, biomaterials, biocompatibility, molecular-cell biology, mechanism of action, medicine, animal modeling, pre-market risk assessments, and post-market safety evaluation. He has published 30 peer-reviewed articles and has been an invited keynote speaker at international conferences, and with multilingual skills (fluent in Japanese, English and Chinese).